{"id":933677,"date":"2026-02-03T09:02:03","date_gmt":"2026-02-03T14:02:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/"},"modified":"2026-02-03T09:02:03","modified_gmt":"2026-02-03T14:02:03","slug":"ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/","title":{"rendered":"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA"},"content":{"rendered":"
\n

\n Access the \u201cWhat This Means\u201d segment\u00a0<\/em>
\n
\n here<\/em>
\n <\/a>\n <\/p>\n

CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics<\/u><\/a> (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor “What This Means” segment<\/a> discussing the Company\u2019s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer.<\/p>\n

As part of the segment, Sanjeev Luther, President & CEO<\/a> of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa\u2019s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the second half of 2026. This reinforces that technology transfer for clinical-grade manufacturing is already underway, accelerating operational readiness and positioning Ernexa to advance its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies designed to target ovarian cancer and autoimmune disease.<\/p>\n

The Virtual Investor \u201cWhat This Means\u201d segment featuring Ernexa can be accessed here<\/a>.<\/p>\n

\n About Ernexa Therapeutics<\/strong>\n <\/p>\n

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancer and autoimmune diseases. Ernexa\u2019s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa\u2019s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.<\/p>\n

ERNA-101 is the company\u2019s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. ERNA-201 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company\u2019s initial focus is to develop ERNA-101 for the treatment of ovarian cancer.<\/p>\n

For more information, visit www.ernexatx.com<\/u><\/a>.<\/p>\n

\n Media Contact<\/strong>
\n
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com<\/u><\/a><\/p>\n

\n Investor Contact<\/strong>
\n
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ENRA@jtcir.com<\/u><\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Access the \u201cWhat This Means\u201d segment\u00a0 here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor “What This Means” segment discussing the Company\u2019s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa\u2019s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the … <\/p>\n

Continue reading “Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-933677","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nErnexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Access the \u201cWhat This Means\u201d segment\u00a0 here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor “What This Means” segment discussing the Company\u2019s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa\u2019s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the … Continue reading "Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T14:02:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA\",\"datePublished\":\"2026-02-03T14:02:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/\"},\"wordCount\":328,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/\",\"name\":\"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=\",\"datePublished\":\"2026-02-03T14:02:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/","og_locale":"en_US","og_type":"article","og_title":"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Market Newsdesk","og_description":"Access the \u201cWhat This Means\u201d segment\u00a0 here CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that it recently participated in a Virtual Investor “What This Means” segment discussing the Company\u2019s recent successful Pre-IND meeting with the U.S. Food and Drug Administration and its continued advancement toward a first-in-human trial for ovarian cancer. As part of the segment, Sanjeev Luther, President & CEO of Ernexa, highlighted how regulatory alignment from the FDA on Ernexa\u2019s development strategy for its lead cell therapy, ERNA-101, provides a clear pathway toward submitting an Investigational New Drug application and initiating clinical testing in the … Continue reading \"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/","og_site_name":"Market Newsdesk","article_published_time":"2026-02-03T14:02:03+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA","datePublished":"2026-02-03T14:02:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/"},"wordCount":328,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/","name":"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=","datePublished":"2026-02-03T14:02:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY0NzQ2MiM3NDA0NTUyIzIyMTAyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ernexa-therapeutics-participates-in-virtual-investor-what-this-means-segment-highlighting-recent-successful-pre-ind-meeting-with-u-s-fda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ernexa Therapeutics Participates in Virtual Investor \u201cWhat This Means\u201d Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933677","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=933677"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/933677\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=933677"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=933677"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=933677"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}